| abstract |
The present invention relates to a phosphonate derivative of purine or pyrimidine of formula (I) below: in which (i) B is a purine or pyrimidine base selected from the group comprising adenine, xhantine, hypoxanthine, guanine, 8-bromoguanine, 8-chloroguanine, 8-aminoguanine, 8-hydrazinoguanine, 8-hydroxyguanine, 8-methylguanine, 8-thioguanine, 2-aminopurine, 2,6-diaminopurine, thymine, cytosine, uracil, 5-bromouracil, 5-iodouracil, 5-ethyluracil, 5-propyluracil, 5-vinyluracil and 5-bromovinyluracil; (ii) R1 is selected from the group consisting of hydrogen, methyl, ethyl, hydroxymethyl and hydroxyethyl; (iii) R2 is chosen from the group comprising a fluorine atom, a hydroxyl group, a BH3 group, a linear or branched alkyl group comprising from 1 to 8 carbons and an amine group R'HN in which R 'is an alkyl group linear or branched comprising from 1 to 8 carbons; and (iv) X is selected from the group consisting of an oxygen atom, a selenium atom and a sulfur atom; and a phosphinate intermediate for obtaining such a phosphonate derivative; a pharmaceutical composition comprising such a phosphonate derivative and the use of such a composition for the preparation for treating and / or preventing a viral infection in a patient. |